Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12327MR)

This product GTTS-WQ12327MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12327MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12050MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ14860MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ3035MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ3437MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ12051MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ3240MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ12270MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ8958MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW